Karachi: The Searle Company Limited released its financial results for the quarter ended September 30, 2026, showing a steady performance amidst challenging market conditions. The pharmaceutical firm reported a slight increase in total assets, amounting to 50.50 billion rupees compared to 49.78 billion rupees as of June 30, 2026.
The company's revenue from contracts with customers was logged at 8.45 billion rupees for the period, a minor move of 1.34% decrease from 8.57 billion rupees in the same quarter last year. Despite the dip in revenue, the gross profit stood at 4.70 billion rupees, reflecting a stable profit margin.
According to information available from the Pakistan Stock Exchange (PSX), The Searle Company Limited’s share capital remained unchanged at 5.88 billion rupees, with capital reserves and revenue reserves contributing significantly to a total equity of 35.67 billion rupees, up from 34.80 billion rupees in the previous quarter. This represents a moderate move in equity growth.
On the liabilities front, the company managed to reduce its total liabilities to 14.83 billion rupees from 14.98 billion rupees, primarily due to a decrease in trade and other payables. The company's current liabilities saw a slight reduction, while non-current liabilities also showed a minor decrease.
The net profit for the quarter was reported at 865.54 million rupees, compared to 853.52 million rupees in the corresponding period of the previous year. The profit before income tax was marginally up at 1.39 billion rupees, indicating a consistent performance over the year.
The earnings per share, both basic and diluted, were reported as 1.47 rupees, marking a slight improvement from 1.45 rupees in the same period last year. The Searle Company Limited continues to maintain a stable financial position, navigating through the economic uncertainties with cautious financial management and strategic planning.
Overall, The Searle Company Limited’s financial results reflect its resilience in maintaining a balanced performance in the pharmaceutical sector for the third quarter of 2026.